LEXICON
No.156 March 9, 2018

G1/G2 Rule
G1/G2ルール

In the FY2018 drug price revision in April 2018, the MHLW is drastically revamping its re-pricing scheme for long-listed products (LLPs) (長期収載品; choki shusai hin), or off-patent brand-name drugs, as it hopes to further accelerate Japan’s shift from LLPs to...

To read the full story

LEXICON

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…